DEXASPORIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXASPORIN (DEXASPORIN).
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
| Metabolism | Primarily hepatic via CYP3A4 isoenzymes; metabolites are excreted renally. |
| Excretion | Renal excretion (80-90% unchanged), biliary/fecal (10-20%) |
| Half-life | 3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min) |
| Protein binding | 25-40% (albumin) |
| Volume of Distribution | 0.2-0.3 L/kg (primarily extracellular fluid; moderate tissue penetration) |
| Bioavailability | IM: 100%; oral: not available (must be parenteral) |
| Onset of Action | IV: immediate; IM: 1-2 h |
| Duration of Action | 6-8 hours (extended to 12-24 h in severe renal impairment) |
| Molecular Weight | 392.46 Da |
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | CrCl > 50 mL/min: no adjustment; CrCl 10-50 mL/min: 50% of usual dose every 12 hours; CrCl < 10 mL/min: 25% of usual dose every 24 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Neonates: 10 mg/kg IV every 12 hours; Infants and children: 1.5 mg/kg IV every 8 hours, maximum 100 mg/dose. |
| Geriatric use | Initiate at lower end of dosing range; adjust based on renal function; monitor for neurotoxicity and ototoxicity. |
| 1st trimester | Avoid. Dexamethasone is a corticosteroid. First trimester exposure is associated with a small increased risk of oral clefts. Use only if clearly needed. |
| 2nd trimester | Use with caution if benefit outweighs risk. May cause fetal adrenal suppression; monitor for intrauterine growth restriction. |
| 3rd trimester | Use with caution. Prolonged use may cause neonatal adrenal suppression; avoid near term unless for fetal lung maturity. |
Clinical note
Comprehensive clinical and safety monograph for DEXASPORIN (DEXASPORIN).
| Placental transfer | Dexamethasone crosses the placenta efficiently with a fetal-to-maternal ratio of approximately 0.5-0.6. It is classified as having relatively high placental transfer compared to prednisolone. |
| Breastfeeding | Dexamethasone enters breast milk in low concentrations. At maternal doses up to 8 mg/day, amounts are unlikely to cause systemic effects in the infant. However, if high doses (>20 mg/day) are used, observe infant for adrenal suppression. Short-term use is generally considered compatible. |
■ FDA Black Box Warning
Long-term use may lead to adrenal suppression and increased risk of infections. Avoid abrupt discontinuation.
| Serious Effects |
Systemic fungal infectionsAdministration of live or live-attenuated vaccinesKnown hypersensitivity to dexamethasone or any component
| Precautions | May mask signs of infection, Increased risk of osteoporosis with prolonged use, Monitor for hyperglycemia, Caution in patients with hypertension or heart failure due to fluid retention |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, spinach, salt substitutes) due to spironolactone's potassium-sparing effect. Grapefruit juice may alter dexamethasone metabolism; avoid concurrent use. Limit sodium to reduce edema. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | DEXASPORIN is contraindicated in pregnancy due to established teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Second and third trimester exposure may cause fetal growth restriction and preterm birth. |
| Fetal Monitoring | Monitor maternal complete blood count weekly, liver function tests, renal function. Fetal ultrasound for growth and anatomy every 4 weeks. Assess for signs of infection. |
| Fertility Effects | DEXASPORIN may cause ovarian suppression leading to amenorrhea and reduced fertility in women. In men, sperm count and motility may decrease; effects are reversible upon discontinuation. |
| Clinical Pearls | Dexasporin is a combination of dexamethasone (glucocorticoid) and spironolactone (potassium-sparing diuretic). Use with caution in hepatic impairment; monitor serum potassium and renal function. Avoid in Addison's disease or hyperkalemia. May mask signs of infection. Taper glucocorticoid dose to avoid adrenal insufficiency. Spironolactone may cause gynecomastia and menstrual irregularities. |
| Patient Advice | Take with food or milk to reduce gastrointestinal irritation. · Do not stop dexamethasone abruptly; follow physician's tapering schedule. · Report sudden weight gain, edema, muscle weakness, or black stools. · Avoid potassium supplements and high-potassium foods unless directed. · Limit sodium intake to minimize fluid retention. · Use caution with NSAIDs or aspirin due to increased GI risk. · May cause dizziness; avoid driving if affected. |